SUPPLEMENT

Q3 2021 — Reconciliation of Non-GAAP Financial Measures

Q3 2021PDF · 6 pages191 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2021 	2020 	2021 	2020
Net Earnings, after tax- as reported 	$3,667 	$3,554 	$16,142 	$12,976
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,159 	1,181 	3,576 	3,426
Litigation expense, net 	2,077 	1,477 	2,054 	2,210
IPR&D 	900 	138 	900 	144
Restructuring related 	121 	130 	333 	363
Acquisition, integration and divestiture related ¹ 	20 	(154) 	(504) 	(1,087)
(Gains)/losses on securities 	(127) 	32 	(335) 	(174)
Medical Device Regulation 	59 	38 	161 	89
Other 	- 	3 	- 	6
Tax Adjustments
Tax impact on special item adjustments 2 	(849) 	(482) 	(1,097) 	(1,002)
Tax legislation and related impacts 	(59) 	(49) 	(713) 	(483)
Adjusted Net Earnings, after tax 	$6,968 	$5,868 	$20,517 	$16,468
Average shares outstanding (Diluted) 	2,674.9 	2,669.3 	2,674.6 	2,670.8
Adjusted net earnings per share (Diluted) 	$2.60 	$2.20 	$7.67 	$6.17
Operational adjusted net earnings per share (Diluted) 	$2.56 	$7.47
Notes:
1
2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Third Quarter 	Nine Months Ended
Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the
divestiture of two Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020
primarily includes a Contingent Consideration reversal ($165M in third quarter and $1,148M in nine months) related to
the timing of certain developmental milestones associated with the Auris Health acquisition.

-- 1 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	5.3% 	13.8% 	8.0% 	10.7%
U.S. 	4.5% 	12.2% 	0.8% 	7.9%
International 	5.9% 	15.9% 	15.4% 	13.8%
WW Currency 	1.2 	0.6 	1.0 	0.8
U.S. 	- 	- 	- 	-
International 	2.2 	1.3 	2.1 	1.7
WW Operational 	4.1% 	13.2% 	7.0% 	9.9%
U.S. 	4.5% 	12.2% 	0.8% 	7.9%
International 	3.7% 	14.6% 	13.3% 	12.1%
General Surgery
Advanced Sterilization Products 	0.4 	0.1
U.S. 	0.0 	0.0
International 	0.8 	0.2
Skin Health / Beauty
Dr. Ci Labo - Sedona 	1.1 	0.2
U.S. 	0.0 	0.0
International 	2.0 	0.4
All Other Acquisitions and Divestitures 	0.5 	0.6 	0.2 	0.4
U.S. 	0.6 	0.0 	0.3 	0.1
International 	0.3 	1.4 	0.0 	0.8
WW Adjusted Operational 	5.7% 	13.8% 	7.6% 	10.6%
U.S. 	5.1% 	12.2% 	1.1% 	8.0%
International 	6.1% 	16.0% 	14.1% 	13.5%
Adjusted Operational Sales Growth
THIRD QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 2 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	5.2% 	13.5% 	23.4% 	14.7%
U.S. 	2.8% 	10.3% 	20.6% 	11.7%
International 	7.3% 	17.5% 	26.0% 	18.0%
WW Currency 	2.1 	2.2 	2.9 	2.3
U.S. 	- 	- 	- 	-
International 	3.8 	5.0 	5.5 	4.9
WW Operational 	3.1% 	11.3% 	20.5% 	12.4%
U.S. 	2.8% 	10.3% 	20.6% 	11.7%
International 	3.5% 	12.5% 	20.5% 	13.1%
General Surgery
Advanced Sterilization Products 	0.6 	0.2
U.S. 	0.0 	0.0
International 	1.2 	0.3
Skin Health / Beauty
Dr. Ci Labo - Sedona 	0.5 	0.1
U.S. 	0.0 	0.0
International 	0.9 	0.2
All Other Acquisitions and Divestitures 	0.5 	0.5 	0.2 	0.4
U.S. 	0.5 	(0.1) 	0.4 	0.1
International 	0.3 	1.3 	0.0 	0.7
WW Adjusted Operational 	4.1% 	11.8% 	21.4% 	13.1%
U.S. 	3.3% 	10.2% 	21.0% 	11.8%
International 	4.7% 	13.8% 	21.7% 	14.4%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
NINE MONTHS 2021 ACTUAL vs. 2020 ACTUAL
Segments

-- 3 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Reported Income/(loss) Before Tax by Segment 	$ 	(636) 	191 	4,259 	3,439 	423 	1,010 	(197) 	(239) 	3,849 	4,401
% to Sales 	-17.2% 	5.4% 	32.8% 	30.1% 	6.4% 	16.4% 	-0.8% 	-1.1% 	16.5% 	20.9%
Intangible asset amortization expense 	103 	104 	799 	828 	257 	249 	- 	- 	1,159 	1,181
In-process research and development 	- 	- 	- 	- 	900 	138 	- 	- 	900 	138
Litigation related 	1,359 	531 	756 	971 	(38) 	(25) 	- 	- 	2,077 	1,477
Loss/(gain) on securities 	1 	(1) 	(135) 	31 	7 	2 	- 	- 	(127) 	32
Restructuring related 	36 	31 	17 	29 	68 	70 	- 	- 	121 	130
Acquisition, integration and divestiture related 	- 	- 	3 	1 	17 	(155) 	- 	- 	20 	(154)
Medical Device Regulation 	- 	- 	- 	- 	59 	38 	- 	- 	59 	38
Other 	- 	- 	- 	- 	- 	3 	- 	- 	- 	3
Adjusted Income Before Tax by Segment 	$ 	863 	856 	5,699 	5,299 	1,693 	1,330 	(197) 	(239) 	8,058 	7,246
% to Sales 	23.3% 	24.4% 	43.9% 	46.4% 	25.5% 	21.6% 	-0.8% 	-1.1% 	34.5% 	34.4%
*Estimated as of 10/19/2021.
Q3 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 4 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Reported Income Before Tax by Segment 	$ 	956 	993 	13,838 	11,787 	3,798 	2,681 	(652) 	(611) 	17,940 	14,850
% to Sales 	8.7% 	9.5% 	36.6% 	35.4% 	18.8% 	16.4% 	-0.9% 	-1.0% 	26.0% 	24.7%
Intangible asset amortization expense 	314 	306 	2,497 	2,378 	765 	742 	- 	- 	3,576 	3,426
In-process research and development 	- 	- 	- 	- 	900 	144 	- 	- 	900 	144
Litigation related 	1,481 	1,169 	675 	1,006 	(102) 	35 	- 	- 	2,054 	2,210
Loss/(gain) on securities 	(19) 	- 	(249) 	(177) 	(67) 	3 	- 	- 	(335) 	(174)
Restructuring related 	91 	69 	54 	70 	188 	224 	- 	- 	333 	363
Acquisition, integration and divestiture related 	- 	- 	(567) 	20 	63 	(1,107) 	- 	- 	(504) 	(1,087)
Medical Device Regulation 	- 	- 	- 	- 	161 	89 	- 	- 	161 	89
Other 	- 	- 	- 	- 	- 	6 	- 	- 	- 	6
Adjusted Income Before Tax by Segment 	$ 	2,823 	2,537 	16,248 	15,084 	5,706 	2,817 	(652) 	(611) 	24,125 	19,827
% to Sales 	25.7% 	24.3% 	43.0% 	45.3% 	28.2% 	17.2% 	-0.9% 	-1.0% 	35.0% 	33.0%
*Estimated as of 10/19/2021.
Q3 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 5 of 6 --

Third Quarter 	Third Quarter
Oct. 3, 2021
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Medical Device
Regulation 	Other
Oct. 3, 2021
Non-GAAP
Cost of products sold 	7,250	$ 	(1,133) 	(18) 	(22) 	6,077
Selling, marketing and admin expenses 	6,000 	(6) 	5,994
Research and development expense 	3,422 	- 	(31) 	3,391
Other (Income) / Expense 	1,850 	(26) 	(2,077) 	(43) 	(20) 	127 	- 	(189)
In-process research and development 	900 	(900) 	-
Restructuring 	60 	(60) 	-
Provision for taxes on income 	182 	165 	433 	202 	22 	(6) 	22 	11 	59 	- 	1,090
Net Earnings 	3,667 	994 	1,644 	698 	99 	26 	(149) 	48 	(59) 	- 	6,968
Third Quarter 	Third Quarter
Sept. 27, 2020
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Medical Device
Regulation 	Other
Sept. 27, 2020
Non-GAAP
Cost of products sold 	6,972	$ 	(1,181) 	(32) 	(18) 	5,741
Selling, marketing and admin expenses 	5,431 	(4) 	5,427
Research and development expense 	2,840 	5 	(16) 	2,829
Other (Income) / Expense 	1,200 	- 	(1,477) 	(30) 	149 	(32) 	(3) 	(193)
In-process research and development 	138 	(138) 	-
Restructuring 	68 	(68) 	-
Provision for taxes on income 	847 	187 	230 	29 	22 	3 	5 	7 	49 	(1) 	1,378
Net Earnings 	3,554 	994 	1,247 	109 	108 	(157) 	27 	31 	(49) 	4 	5,868
Nine Months 	Nine Months
Oct. 3, 2021
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Medical Device
Regulation 	Other
Oct. 3, 2021
Non-GAAP
Cost of products sold 	21,900	$ 	(3,550) 	(65) 	(59) 	18,226
Selling, marketing and admin expenses 	17,505 	(17) 	17,488
Research and development expense 	9,994 	- 	(85) 	9,909
Other (Income) / Expense 	480 	(26) 	(2,054) 	- 	(99) 	504 	335 	- 	(860)
In-process research and development 	900 	(900) 	- 	- 	-
Restructuring 	169 	(169) 	-
Provision for taxes on income 	1,798 	505 	432 	202 	59 	(104) 	(27) 	30 	713 	- 	3,608
Net Earnings 	16,142 	3,071 	1,622 	698 	274 	(400) 	(308) 	131 	(713) 	- 	20,517
Nine Months 	Nine Months
Sept. 27, 2020
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Medical Device
Regulation 	Other
Sept. 27, 2020
Non-GAAP
Cost of products sold 	20,613	$ 	(3,426) 	(69) 	(40) 	17,078
Selling, marketing and admin expenses 	15,627 	(10) 	15,617
Research and development expense 	8,127 	- 	(39) 	8,088
Other (Income) / Expense 	545 	- 	(2,210) 	(107) 	1,087 	174 	(6) 	(517)
In-process research and development 	144 	(144) 	-
Restructuring 	187 	(187) 	-
Provision for taxes on income 	1,874 	550 	373 	30 	65 	10 	(42) 	16 	483 	- 	3,359
Net Earnings 	12,976 	2,876 	1,837 	114 	298 	(1,097) 	(132) 	73 	(483) 	6 	16,468
(1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States. 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition.
In-process
research and
development
Acquisition,
integration and
divestiture related (1)
(Loss)/Gain on
securities
Tax legislation
and other tax
related
In-process
research and
development
Acquisition,
integration and
divestiture related
(Loss)/Gain on
securities
Tax legislation
and other tax
related
Year to Date
In-process
research and
development
Acquisition,
integration and
divestiture related (1)
(Loss)/Gain on
securities
Tax legislation
and other tax
related
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
Acquisition,
integration and
divestiture related
(Loss)/Gain on
securities
Tax legislation
and other tax
related

-- 6 of 6 --